tbuckley/cabot-search huggingface dataset:
AB0543 Factors associated with work disability in patients with ankylosing spondylitis
Authors: J. D. Castillo-Ortiz, S. Ramiro, R. Landewé, D. van der Heijde, M. Dougados, F. van den Bosch, A. Boonen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Ankylosing Spondylitis (AS) usually affects patients in early years of life, when the professional career is one of the individual's primary social roles. In addition, work disability (WD) represents the major driver of the total cost-of-illness of the disease. <h3>Objectives</h3> To describe and to explore WD in a cohort of patients with AS, as well as their associated factors, and to compare the prevalence of WD in AS with the one of the general population. <h3>Methods</h3> Data on work outcome and clinical characteristics were obtained from patients followed in the Outcome in AS International Study (OASIS) which included patients from the Netherlands, France and Belgium. Data from the baseline assessment were used. Logistic regression (univariable followed by multivariable) was used to investigate factors associated with WD. Prevalence of work disability in Dutch patients included in OASIS and with working age (n=130) was compared with the one of the general population (source: official statistics office, cbs.nl) through indirect standardization adjusting for age and gender. Comorbidity was tested as independent variable using comorbidity index (range 0-9, the higher the more comorbidities). <h3>Results</h3> Of 215 patients included in this study (mean age 43.5 (SD12.5) years, mean disease duration 11.4 (SD 9.1) years, 71 % male, 80% HLA-B27), 26% (n=55) were full-work disabled and 58% (n=124) were working at baseline. In multivariable analysis older age (OR 1.08; 95% CI 1.02-1.13), Dutch origin (OR 4.59; 95% CI 1.25-16.85), high comorbidity index (OR 2.31; 95% CI 1.13-4.7), poor function, i.e. higher BASFI (OR 1.49; 95% CI 1.19-1.88) and high disease activity, i.e. ASDAS (OR 2.01; 95% CI 1.08-3.72) were significantly associated with WD (Table). The risk for being WD among Dutch patients (n=130, of which 47 were WD) was 5.6 (95% CI 4.1-7.1) for males and 6.4 (95% CI 3.6-9.14) for females, times higher than expected compared to general population. <h3>Conclusions</h3> In this prevalence cohort of patients with AS, the prevalence of WD is quite high (26%). Among Dutch patients in working age the risk of WD was 6 times higher than the expected risk. Not only disease related variables (function, activity and comorbidity), but also contextual factors (age and Dutch origin) were significantly associated with WD. <h3>Disclosure of Interest</h3> None Declared
Minute perforation after argon plasma coagulation for management of small colonic polyps
Authors: C.-H. Chuang, T.-C. Chou, C.-Y. Chen
Journal: Endoscopy (2009)

A 53-year-old woman presented with a 6-month history of chronic constipation and abdominal bloating. Because of concern about a colorectal lesion, colonoscopy was done and hundreds of small polyps were found throughout the colon, most being less than 4 mm in diameter. Some of the bigger polyps were removed by polypectomy and were found at pathologic examination to be tubular adenoma. As the patient was unwilling to undergo a rectum-preserving total colectomy, argon plasma coagulation (APC) was selected to ablate the remaining polyps as far as possible ([Fig. 1]).
Prostate Cancer Genetics Research Picks Up Pace
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Prostate Cancer Genetics Research Picks Up Pace Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 15, 3 August 1994, Pages 1112–1115, https://doi.org/10.1093/jnci/86.15.1112 Published: 03 August 1994
sLOX-1の温和な上昇であっても,非AMI冠動脈疾患患者における冠動脈硬化症プラーク負荷が反転する可能性がある
Authors: Inami Toru, Yamamoto Masanori, Kimata Nakahisa, Okada Kaoru, Tara Shuhei, Murakami Daisuke, Tajika Kenichiro, Yodogawa Kenji, Hayashi Meiso, Ohno Norihiko, Ohba Takayoshi, Aoki Satoshi, Ibuki Chikao, Yokoyama Shinya, Hata Noritake, Takano Masamichi, Seino Yoshihiko, Mizuno Kyoichi, Kume Noriaki
Journal: Circulation (2009)
Bone Imaging in SAPHO Syndrome
Authors: VIRGINIA PEIRÓ, ISABEL FREILE, F. JAVIER DE HARO, CARLOS ISASI, ANTONIO LARREA, JOSE ORTIZ BERROCAL
Journal: Clinical Nuclear Medicine (1998)

The acronym SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) stands for a recently described syndrome of unknown cause and pathogenesis that may be related to the seronegative spondyloarthropathies. We present the case of a 17-year-old boy who reported lower limb pain that rendered him unable to walk. He was receiving isotretinoin to treat severe acne. There was no response to treatment with different analgesics (morphine, intravenous anesthetics), and the intensity and extension of the pain increased progressively, leaving him bedridden. SAPHO syndrome was diagnosed, and high-dose nonsteroid anti-inflammatory therapy was begun, resulting in a favorable outcome.
Abstract 3702: Cumulative incidence rates of breast cancer for Filipinos and Chamorros in Guam and the United States
Authors: Grazyna Badowski, Rachael Leon Guerrero, Brayan Simsiman, Rachel Novotny, Lynne Wilkens
Journal: Cancer Research (2015)

Abstract Background Breast cancer is the leading cause of cancer-related death among women on Guam. However incidence rates vary between Chamorros and Filipinos, the two predominant ethnic groups on Guam. Objective Our objective was to compare age-specific cumulative incidence rates among ethnic groups in Guam and US. Cumulative incidence rates are relatively stable and thus provide a good estimate of cumulative risk of breast cancer. Methods This study included all breast cancer cases (n = 576) reported to the Guam Cancer Registry from 2000 to 2009 and all breast cancer cases (n = 678,637) reported to the Surveillance, Epidemiology,and End Results (SEER) 18-Registry Database. Cumulative incidence rates were calculated for Filipinos and Chamorros for two time periods: 2000-2004 and 2005-2009. For comparison, cumulative incidence rates were also calculated for all women in Guam and the US, and for Filipino only in the US. Results Remarkable differences were seen in cumulative incidence rates by age and ethnicity. During the 2000-2004 time period, the cumulative incidence rates by age 40 in Filipinos on Guam were the highest (0.7%) and almost threefold higher than the rate in Chamorros (0.24%). But after age 40, the rates for Chamorros increased rapidly. The lifetime cumulative incidence rates (age 0-75) for Chamorros was highest in Guam (11.4%) and close to the US rate (12%). Interestingly, there was a marked difference in lifetime cumulative incidence rates between Filipino women in Guam and Filipinos in the US (7% and 10.9% respectively). Similar results were found for the 2005-2009 time period. Conclusions The observed disparity among ethnic groups suggests ethnic differences in exposure or response to certain risk factors. Further study is needed to examine possible differences in risk behaviors between Filipinos and Chamorros in Guam, as well as between Filipinos in Guam and Filipinos in the US. Citation Format: Grazyna Badowski, Rachael Leon Guerrero, Brayan Simsiman, Rachel Novotny, Lynne Wilkens. Cumulative incidence rates of breast cancer for Filipinos and Chamorros in Guam and the United States. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3702. doi:10.1158/1538-7445.AM2015-3702
AB0751 Efficacy of Ustekinumab in Patients with Active Psoriatic Arthritis: 1 Year Results
Authors: M.-J. Rioux, E. Rioux, I. Fortin
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Psoriatic arthritis (PsA) is characterised by arthritis, psoriasis, sacroilitis, enthesitis and dactylitis. The efficacy of tumor necrosis factor-α (TNF-α) inhibitor has been demonstrated in different controlled clinical trials and observational studies. However, some patients have inadequate response to TNF-α inhibitors and no alternative mechanism of action is available for those who failed more than one anti-TNF. Ustekinumab is an efficacious treatment for psoriasis and may be useful in patients with active psoriatic arthritis. <h3>Objectives</h3> The objective of this study was to assess in Canadian clinical practice the efficacy of ustekinumab in patients with psoriatic arthritis who failed to one or more TNF-α inhibitors agents. <h3>Methods</h3> Charts of patients taking ustekinumab at the Centre de Rhumatologie de l9Est du Québec were reviewed and detailed data including demographic information, disease characteristics, 28-joint disease activity score (DAS28-CRP), BASDAI, BASFI, SPARCC and Health Assessment Questionnaire-Disease Index (HAQ-DI) were collected. Descriptive statistics were used to describe patients initiating ustekinumab in this real-world setting. <h3>Results</h3> A total of 9 patients starting treatment with ustekinumab were enrolled in this study. Patients have failed an average of 3.66 anti-TNF agents. Overall, DAS28-CRP decreased from 4.39 at baseline to 3.84 at month 12. HAQ-DI decreased from 1.97 to 1.52. BASDAI decreased from 8.16 to 6.9. BASFI decreased from 7.18 to 5.70. SPARCC increased from 2 to 3.66. Mean number of dactylitis decreased from 4.22 to 0. Finally, all patients have improved their psoriasis after 12 months. Two patients discontinued the treatment because of a secondary failure and an adverse event (nausea, low back pain). <h3>Conclusions</h3> The present study suggests that ustekinumab improved active psoriatic arthritis and may offer an alternative treatment for patients who failed to respond to their previous anti-TNF. The most impressive effect is the improvement of enthesitis and dactylitis. It is even more interesting that the response was good nevertheless the number who have failed to an anti-TNF. This suggests that another mode of action will probably be a part of the treatment in PsA as it is in rheumatoid arthritis. However, this is an exploratory study and a larger sample is needed for better interpretation. <h3>References</h3> McInnes et al., 2013. Efficay and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780-789. Mease, P.J., 2011. Measures of psoriatic arthritis, Arthritis Care and Research, 63(S11): S65-S85 GRAPPA, 2013. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3688
Abstract 1930: Trends of invasive and in-situ melanoma diagnosis in the U.S
Authors: Jiali Han, Erin Wei, Abrar A. Qureshi
Journal: Cancer Research (2011)

Abstract Melanoma, accounts for about 4% of skin cancer cases, but is associated with 79% of skin cancer deaths. The number of new cases of melanoma in the US is rising dramatically. The incidence of in-situ melanoma is increasing at a more rapid rate than for melanoma overall. This may be due to better awareness, improved screening techniques and access to dermatologists that result in early diagnosis of melanoma. There is also concern that over the last few years, pathologists have had a lower threshold to diagnose in-situ melanoma due to medico-legal reasons. However, the lesions that are being called in-situ melanoma are most certainly severely dysplastic (atypical) nevi that are considered melanoma precursor lesions. The distinction is important to make an accurate diagnosis when providing medical care to a patient. We investigated the trend of diagnosis and melanoma invasive versus in situ in three national prospective cohorts of women and men: Nurses’ Health Study I (1976-2008, age at enrollment 30-55), Nurses’ Health Study II (1989-2007, age at enrollment 25-42), and Health Professionals Follow-up Study (1986-2008, age at enrollment 40-75). We accrued 940 invasive and 424 in situ cases in NHS I, 447 invasive and 326 in situ cases in NHS II, and 310 invasive and 153 in situ cases in HPFS. In each cycle of 2-year follow-up, the incidence rate of melanoma steadily increased, and the increased incidence rate of in-situ melanoma was substantially greater than invasive melanoma. These trends were similar in all three cohorts. The ratio of invasive and in-situ melanoma in each cycle 2-year follow-up decreased more than 5 folds over the follow-up period in the NHS I and II. The decrease was not apparent in HPFS. In this study, we found that in-situ melanoma incidence has continued to rise in the US in the last few decades, especially among women where the rate of in-situ melanoma increased more sharply compared to invasive melanoma incidence. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1930. doi:10.1158/1538-7445.AM2011-1930
Serrated carcinoma arising from a sessile serrated adenoma
Authors: E.-J. Lee, M.-J. Kim, J. Suh, S. Lee
Journal: Endoscopy (2013)

Sessile serrated adenoma/polyp (SSA/P), a distinct serrated polyp subtype, can progress to colorectal cancer via the serrated neoplasia pathway [1]. On endoscopic examination, SSA/Ps usually show a flat or sessile appearance, a mucus covering, and a type II pit pattern. The endoscopic findings of uncomplicated SSA/Ps are well known; however, the endoscopic features of serrated carcinomas arising from SSA/Ps have not been fully described [2] [3]. Herein, we report a case of serrated carcinoma arising from an SSA/P in a 66-year-old man who underwent endoscopic submucosal dissection (ESD) following colorectal cancer screening.
Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
Authors: William H. West, Kurt W. Tauer, John R. Yannelli, Gailen D. Marshall, Douglas W. Orr, Gary B. Thurman, Robert K. Oldham
Journal: New England Journal of Medicine (1987)

Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but has been associated with severe fluid retention and cardiopulmonary stress. In an effort to preserve the efficacy but reduce the toxicity of this treatment, we used escalating doses of rIL-2 as a constant infusion rather than as a bolus dose. Forty-eight patients with advanced cancer received rIL-2 as a 24-hour infusion in five-day cycles separated by five-day periods of rest and leukapheresis. Eight patients were removed from the study before receiving cells activated in vitro. In the 40 who could be evaluated for their response, there were 13 partial responses (32.5 percent) and 2 minor responses. Partial responses were observed in Hodgkin's disease (one of one), non-Hodgkin's lymphoma (one of one), lung cancer (one of five), ovarian cancer (one of one), parotid cancer (one of two), renal cancer (three of six), and melanoma (five of ten). Responses were associated with a good performance status, a base-line lymphocyte count above 1400 per cubic millimeter, and an rIL-2-induced lymphocyte count of at least 6000. Optimal lymphocytosis required a priming dose of rIL-2 of 3 X 10(6) U per square meter of body-surface area per day, and 15 of 28 patients receiving this priming dose responded to treatment. A weight gain of more than 10 percent of total body weight (five patients) and dyspnea at rest (six patients) were unusual events restricted to patients with poorer pretreatment performance. We conclude that the administration of rIL-2 as a constant infusion may preserve the antineoplastic activity of adoptive immunotherapy while increasing the safety and comfort of patients.
OPTIMAL CUTOFF VALUE OF ANNUAL CORONARY ARTERY CALCIUM SCORE PROGRESSION BY SERIAL CORONARY CALCIUM SCAN PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ASYMPTOMATIC KOREAN POPULATION
Authors: Hyung Bok Park, Chae-Wan Lim, Jae-Hyuk Lee, Hyun-Jin Kim, Yong-Sung Seo
Journal: Journal of the American College of Cardiology (2016)
PULMONARY ARTERY PRESSURE MANAGEMENT IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION SIGNIFICANTLY REDUCES HEART FAILURE HOSPITALIZATIONS AND MORTALITY ABOVE AND BEYOND BACKGROUND GUIDELINE-DIRECTED MEDICAL THERAPY
Authors: William T. Abraham, Philip Adamson, Lynne Stevenson, Maria Rosa Costanzo, Robert Bourge, Jordan Bauman, Jay Yadav
Journal: Journal of the American College of Cardiology (2015)
AT-45 * GAMMA KNIFE RADIOSURGERY FOR RECURRENT HIGH GRADE GLIOMAS
Authors: S. Peker, I. A. Kabalay, E. Tezcanli, M. Yilmaz, M. Sengoz
Journal: Neuro-Oncology (2014)

OBJECT: In this study, we aimed to review our experience with Gamma Knife radiosurgery (GKRS) for the treatment of recurrent high grade glial tumors. METHODS: We retrospectively reviewed 39 patients who were treated for focally recurrent high grade gliomas with GKRS at our institution between May 2006 and August 2013. Twenty-four males and 15 females with a median age of 51 years (range 19-80 years) were included in the study. Histopathology included 31(79%) glioblastomas (GBM), 5 (13%) anaplastic astrocytomas, 2 (5%) anaplastic oligoastrocytomas and 1 (3%) anaplastic oligodendroglioma. All patients underwent initial surgery followed by radiotherapy, 34 (87%) patients received chemotherapy before GK treatment. The median tumour volume was 4,90 cc (range:0.30-26.60 cc) and the median marginal dose was 15 Gy (range:12-18 Gy). RESULTS: Median overall survival for the whole cohort from the day of GKRS was 18 months (range: 2–78 months). One and 2 years survival rates were %70 and %55, respectively. For GBM patients, the median overall survival, 1 and 2 years survival rates were 17 months (range: 2– 46 months), 61% and 23%, respectively. Patients with WHO grade III gliomas had a median overall survival, 1 year and 2 years survival rates of 27 months (range: 5– 78 months), 75% and 50%, respectively. CONCLUSION: In the highly selected patients with focally recurrent high grade glial tumors, GKRS can contribute to prolonged survival rates.
Abstract 2585: Snail-p53 interaction inhibitor GN25 and its combination with Oxaliplatin targets both hedgehog signaling and K-ras pathway in pancreatic cancer
Authors: Asfar S. Azmi, Bum-Joon Park, Ramzi M. Mohammad
Journal: Cancer Research (2011)

Abstract Activation of hedgehog (Hh) signaling is widely observed in human cancers including pancreatic cancer (PC). Similarly, mutations in K-Ras gene is found in &amp;gt;80% of PC. Constitutive activation of Hh signaling component Gli in turn enhances p53 suppressor Snail. Studies from our group have revealed that p53 is further suppressed by direct binding with oncogenic K-Ras-induced Snail. Therefore in order to target combined suppressive effects of Hh signaling and K-Ras-induced snail on p53 pathway, a specific inhibitor of the p53-Snail binding (GN25) was developed. This inhibitor can induce p53 expression and functions in K-Ras-mutated cells, with no toxicity to normal cells (Oncogene 2010). Here we show that GN25 when combined with Oxaliplatin induces synergistically (combination index CI&amp;lt;1) enhanced growth inhibition (MTT) and apoptosis (Histone DNA ELISA and Annexin V FITC) in multiple PC cell lines (AsPC-1, Capan-2, BxPC-3 and Colo-357) irrespective of the mutational or functional status of both p53 and K-Ras. Interestingly, we found that some of the above cell lines have hyper activation of Hh signaling that results in constitutively over activation of Gli. Western blot analysis demonstrated that GN25/oxaliplatin re-activated the p53 protein and downstream effector molecules such as pro-apoptotic Bax and cell cycle regulator p21. Further analysis showed that GN25/oxalipltin interferes with the Hh signaling and suppresses Snail. In SCID mice studies in vivo, the maximum tolerated dose of GN25 was found to be 35 mg/kg i.v. In addition, it can be given in combination with oxaliplatin at 5 mg/kg i.p twice a week for two weeks. The combination studies of GN25/oxaliplatin in multiple tumor xenografts (wt-k-Ras BxPC-3 and AsPC-1 mut-p53 k-Ras) are ongoing. So far our results suggest that GN25/oxaliplatin is a strong combination against hyper activated Hh and mutant K-Ras-initiated human pancreatic cancer irrespective of mutational status of p53. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2585. doi:10.1158/1538-7445.AM2011-2585
Abstract 5408: PEG surface modification of Poly(D/L Asp-DET)/DNA polyplexes greatly increases tumor accumulation and improves biodistribution
Authors: Janni Mirosevich, Gregoire Cardoen, Brian Burke, Tara Costich, Kevin Sill
Journal: Cancer Research (2011)

Abstract Cationic polymers have received much attention as promising non-viral vectors for gene transfer. However, generating polymers that are stable and can systemically deliver large amounts of nucleic acids to specific disease sites continues to be a significant hurdle to non-viral vector success. Therefore, the purpose of this study was to develop a new biocompatible and biodegradable cationic polymer system for non-viral gene delivery of plasmid DNA. Poly-d/l Aspartate-Diethylenetriamine [Poly(d/l Asp-DET)] polymers were synthesized and used to complex plasmid DNA. Polymer/DNA polyplexes were further modified by covalent coupling with various polyethylene glycol (PEG) polymers. Polyplexes were characterized and evaluated for particle size, zeta potential and morphology by TEM. Plasmid DNA stability was assessed by challenging polyplexes with serum nucleases, and the efficacy of DNA delivery and gene expression was examined by performing transfection experiments on cancer cells. In vivo DNA tumor delivery and biodistribution was also investigated using tumor bearing nude mice. Poly(d/l Asp-DET) polymers were able to bind to plasmid DNA and formed polyplex particles the were amenable to surface coating with PEG. PEG-Polyplexes were approximately ∼70nm in diameter with neutral zeta potentials. TEM confirmed that the polyplexes were uniform in size. PEG-Polyplexes were also extremely stable and maintained the structural integrity of DNA following incubation in nucleases, and were also capable of transfecting HCT-116 and PC-3 culture cells with no cell toxicity. Tail vein administration of PEG-Polyplexes to tumor bearing nude mice did not reveal any observable toxicities. Moreover, improvements in PEG polymer chemistry increased nucleic acid accumulation in tumors while reducing DNA accumulation in other tissues including liver, kidney and spleen. Poly(d/l Asp-DET) cationic polymers show enormous potential as non-viral drug delivery agents. Further, the surface modification of polyplexes with PEG allowed for sustained systemic delivery of nucleic acids to tumors. The characterization of PEG-Poly(Asp-DET)/DNA polyplexes provides useful insights that can be used to the design vectors for targeted nucleic acid delivery. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5408. doi:10.1158/1538-7445.AM2011-5408
European Drug Agency Promises Quicker Approvals
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article European Drug Agency Promises Quicker Approvals Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 14, 19 July 1995, Pages 1050–1051, https://doi.org/10.1093/jnci/87.14.1050 Published: 19 July 1995